Under construction – not a live service
Sign in
Taking people in Saudi ArabiaNo phase

How dupilumab affects anxiety and depression in moderate-to-severe atopic dermatitis

Observes mood and quality of life in people with atopic dermatitis taking dupilumab.

Key facts

Who runs it
Sanofi
Where
Jeddah, Saudi ArabiaSee the 2 sitesAlso in 2 other countries, 5 sites
Trial code
Registry title
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
Status
Recruiting
People taking part
184 people, planned
Started
24 Feb 2026
Expected to end
24 May 2027
Type of study
Observational
Treatments tested
  • Dupilumab
Record updated
28 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with moderate to severe atopic dermatitis who also have signs of anxiety or depression and are starting dupilumab.

Age
12 years and older
Sex
All sexes can join.
Disease stage
Moderate to severe atopic dermatitis, with signs and symptoms of anxiety and/or depression.
Earlier treatment
Must start dupilumab within 30 days of enrolment, as decided by the treating doctor. Must not have taken antidepressants or anti-anxiety medicines in the 6 months before enrolment.

Main reasons for not taking part

  • Pregnant, breastfeeding, or planning pregnancy in the next 6 months
  • Taking part in another trial
  • Active infection needing treatment through the body (systemic treatment), or an active parasite infection or high risk of one
  • HIV, hepatitis B or C, cancer, or other illnesses at the same time
  • Using or planning to use antidepressants or anti-anxiety medicines

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Participants who have moderate to severe AD with signs and symptoms of anxiety and/or depression
  • Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation
  • Participants and/or their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent

Who cannot take part

  • Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses
  • Participants on antidepressants/anti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants/anti-anxiety. In addition, those who will use antidepressants/anti-anxiety medications throughout the study will be excluded from the analysis; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
  • Participants with active chronic or acute infection requiring systemic treatment
  • Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection
  • Females who are pregnant, lactating, or planning/intending to be pregnant in the next 6 months
  • Participants who are participating in another trial

Where in Saudi Arabia

Also in 2 other countries, 5 sites

  • Investigational Site: Saudi Medical Services (Medical Fakeeh)Jeddah, Saudi ArabiaTaking people
  • Investigational Site: King Faisal Specialist HospitalJeddah, Saudi ArabiaNo longer taking part

About the trial

What the trial wants to find out

This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.

Treatments tested

  • Dupilumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
Plain-language title
How dupilumab affects anxiety and depression in moderate-to-severe atopic dermatitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
28 July 2026